IO-Resp

  • Therapy response prediction to immuno-oncology drugs in ovarian cancer
  • IO-Resp is a 2cureX project financed by a 780.000 EUR grant from the “SME-innovative – medical technology” Program of the German Federal Ministry of Education and Research. The IO-Resp objective is to expand the ability of 2cureX’s IndiTreat® test so that it can predict the responses to immune-oncology drugs.
  • IO-Resp started in April 2020 and will run for 36 month.
  • Partner to the IO-Resp project is the University medical center Hamburg Eppendorf (UKE). The Department of Gynecology and the Acute Leukemia Lab of the Department of Oncology provide expertise in novel drug therapy approaches for the treatment of ovarian cancer patients. 2cureX sees an active exchange between hospital professionals and patients as key in future treatment of cancer patients.
  • The funds ensure that the assay principle underlying the functional precision medicine test developed by 2cureX can be adapted so that IndiTreat® can be used to pre-therapeutically measure an ovarian cancer patient’s sensitivity to various check-point inhibitors. In addition it supports establishing a R&D presence in the fields of drug sensitivity testing immuno-oncology and ovarian cancer.

Project Details

Acronym:
IO-Resp Grant agreement

ID:
13GW0407A

Duration:
36 months

Start date:
1 April 2020

Topic:
SME-innovative – medical technology

Funding:
780.000 EUR

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.